



12 March 2013

Manager Companies
Companies Announcement Office
ASX Limited
20 Bridge Street
SYDNEY NSW 2000

Dear Sir

Sun Biomedical Limited – Appendix 3Y

We enclose a copy of Appendix 3Y – Change of Director’s Interest Notice for Mr Evan Cross.

We note that this notice is being lodged outside of the prescribed date of lodgement. The late lodgement of the Appendix 3Y was as a result of an administrative oversight by the former Company Secretary and not the Director’s failure to notify the Company of the change of holding in the Company’s securities.

The Company reaffirms that the Directors of the Company have agreed to be bound by the policy for trading in the Company’s securities as referred to in the Company’s Corporate Governance Statement and, in particular, its Securities Trading Policy.

The Company is of the view that the arrangements regarding trading in the Company’s securities are sufficient to ensure that the market is notified within the time frame set out in ASX Listing Rule 3.19A.2.

Yours faithfully

A handwritten signature in black ink, appearing to read 'Peter Webse', is positioned above the printed name and title.

Peter Webse
Company Secretary

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Sun Biomedical Limited
ABN	18 001 285 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Evan George Cross
Date of last notice	1 March 2012

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	a. Shares held in the name of Fullerton Private Capital Pty Ltd (Director and Shareholder); and b. Shares held in the name of Manhattan Investments Pty Ltd (Director and Shareholder).
Date of change	a. 14 December 2012; and b. 14 December 2012.
No. of securities held prior to change	a. 21,428,572 Shares (after 14:1 consolidation on 2/10/2012); and b. 1,339,286 Shares (after 14:1 consolidation on 2/10/2012).
Class	Shares
Number acquired	a. 8,000,000 Shares; and b. 1,339,286 Shares.
Number disposed	Nil
Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	a. \$56,000.00; and b. \$9,375.00.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	a. 29,428,572 Shares; and b. 2,678,572 Shares.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take up under non-renounceable rights issue on 14 December 2012

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Issued pursuant to non renounceable rights issue
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.